Rep. Ro Khanna and his household cycled roughly $57,000 through ABT, the medical device and healthcare giant Abbott Laboratories, in a five-week burst of buying and selling between late February and the end of March.
The California Democrat reported four separate transactions in the stock, including a late-February purchase followed by three March sales. The activity spanned accounts held by the lawmaker, a dependent child and his spouse, according to disclosure filings.
A quick round trip
The trades, as disclosed under the STOCK Act’s 45-day reporting requirement, break down as follows:
- Feb. 24, 2026: Buy, $1,000–$15,000 (Dependent Child)
- Mar. 10, 2026: Sell, $1,000–$15,000 (Self)
- Mar. 23, 2026: Sell, $15,000–$50,000 (Spouse)
- Mar. 30, 2026: Sell, $1,000–$15,000 (Dependent Child)
In total, the disclosed value of the transactions is estimated at about $57,000, based on the midpoint of the reported ranges. The pattern suggests a brief accumulation followed by a rapid unwind, with the largest move coming from a mid-March sale by Khanna’s spouse valued between $15,000 and $50,000.
Abbott Laboratories, which trades on the New York Stock Exchange and carries a market capitalization of roughly $187.7 billion, was recently priced at $108.03. The stock has traded in a 52-week range of $105.27 to $139.06, placing it near the lower end of that band during the period of Khanna’s transactions.
Healthcare exposure and committee roles
Khanna serves on the House Armed Services Committee and the House Committee on Oversight and Government Reform, as well as the Select Committee on the Strategic Competition Between the United States and the Chinese Communist Party. Abbott’s portfolio spans diagnostics, medical devices, nutrition and branded generic pharmaceuticals — sectors that can intersect with federal procurement and military healthcare systems overseen by Armed Services.
While Abbott is not primarily a defense contractor, the Pentagon is a major healthcare provider through TRICARE and military treatment facilities, making large healthcare suppliers perennially relevant to congressional oversight and budgeting decisions.
Khanna has been one of the more active traders in Congress in recent years, with 17,672 career transactions disclosed. Abbott is also widely held on Capitol Hill: at least 75 lawmakers have reported trading the stock, reflecting its status as a blue-chip healthcare name commonly found in diversified portfolios.
The March sales came during a period of broader market volatility tied to shifting expectations around interest rates and healthcare spending. Abbott shares hovered just above their 52-week low at the time, suggesting the household may have been trimming exposure rather than exiting at a peak.
The transactions add to a steady stream of activity by the congressman and his family members, whose filings are regularly tracked alongside other latest congressional trades. As with all members of Congress, Khanna is required to publicly disclose stock trades but is not prohibited from buying or selling individual equities.
Whether the late-February purchase and subsequent March sales represent short-term portfolio rebalancing or a tactical shift in healthcare exposure, the net effect was clear: a swift reversal in Abbott holdings within just over a month.